Precision BioSciences Reports Positive 2024 Financial Results

Precision Biosciences ( (DTIL) ) has released its Q4 earnings. Here is a breakdown of the information Precision Biosciences presented to its investors.

Precision BioSciences, Inc. is a clinical stage gene editing company utilizing its proprietary ARCUS platform to develop in vivo gene editing therapies for diseases with high unmet needs. In its latest earnings report, Precision BioSciences highlighted significant progress in its gene editing programs, including the commencement of a Phase 1 clinical trial for its PBGENE-HBV program targeting chronic Hepatitis B and positive clinical responses in its partnered program for Ornithine Transcarbamylase Deficiency. The company reported a net income of $7.2 million for the fiscal year 2024, a substantial improvement from the previous year’s loss, driven by increased revenues from new licensing agreements. Despite a decrease in quarterly revenues, the company remains financially stable with a cash runway extending into the second half of 2026, supporting ongoing clinical trials. Looking ahead, Precision BioSciences aims to continue advancing its gene editing programs and achieve key clinical milestones, leveraging its ARCUS platform to address a broad range of genetic and infectious diseases.